Gilead Sciences, Inc. 2025 Q3 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Gilead Sciences, Inc. is a biopharmaceutical company focused on HIV, viral hepatitis, cancer, and inflammation. The company operates as a large accelerated filer with headquarters in Foster City, California. As of October 31, 2025, there were approximately 1.24 billion shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $7,769 million | $7,545 million | $21,518 million | $21,185 million |
| Net Income (Attributable to Gilead) | $3,052 million | $1,253 million | $6,327 million | ($1,303 million) |
| Diluted EPS | $2.43 | $1.00 | $5.04 | ($1.04) |
| Operating Income | $3,327 million | $888 million | $8,038 million | ($790 million) |
| Product Gross Margin | 78.6% | 79.1% | 78.1% | 77.8% |
| Cash and Cash Equivalents | $7,330 million | $5,037 million (Q3 2024) | Balance Sheet: $7,330 million (Sep 30, 2025) | |
| Total Debt (Net) | $24,941 million | $26,710 million (Dec 31, 2024) | Includes $2,806 million current portion | |
| Operating Cash Flow (9M) | $6,692 million | $7,853 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% in Q3 2025 and 2% for the nine months ended September 30, 2025, compared to the prior year. This was driven by higher HIV and Liver Disease product sales and a significant increase in royalty, contract, and other revenues.
- Profitability Surge: Net income improved dramatically from a loss of $1.3 billion in the nine months of 2024 to a profit of $6.3 billion in 2025. This turnaround is primarily due to the absence of large non-recurring impairment charges and acquired in-process research and development (IPR&D) expenses that impacted the prior year.
- Product Performance:
- HIV: Biktarvy sales increased 6% (Q3) and 7% (9M); Descovy sales increased 20% (Q3) and 30% (9M).
- Liver Disease: Sales increased 12% (Q3) and 3% (9M), driven by Livdelzi and chronic hepatitis B products.
- Veklury: Sales decreased 60% (Q3) and 52% (9M) due to lower COVID-19 hospitalization rates.
- Oncology: Trodelvy sales increased 7% (Q3) and 6% (9M), while Cell Therapy sales declined 11% (Q3) and 7% (9M) due to competitive headwinds.
- Unusual Items: Royalty, contract, and other revenues jumped to $424 million in Q3 2025 (from $30 million in Q3 2024) due to the recognition of $400 million of previously constrained revenues from the sale of certain intellectual property.
Guidance, Outlook, and Risks
- Recent Developments:
- Trodelvy (ASCENT-07): In November 2025, Gilead announced the Phase 3 ASCENT-07 study for Trodelvy in HR+/HER2- metastatic breast cancer did not meet its primary endpoint of progression-free survival. Management does not currently anticipate an impairment of the associated finite-lived intangible asset but notes potential future adverse changes could impact results.
- Biktarvy Patent Litigation: Settlement agreements with generic manufacturers (Lupin, Cipla, Laurus) were reached in October 2025, delaying generic entry in the U.S. to April 1, 2036, extending exclusivity beyond previous projections.
- Acquisitions: Closed the acquisition of Interius BioTherapeutics for approximately $350 million in October 2025.
- Tax Matters: A settlement with a tax authority in October 2025 is expected to result in a $450 million income tax benefit recognized in Q4 2025. The "One Big Beautiful Bill" Act enacted in July 2025 had no material impact on Q3 income tax expense.
- Risks:
- Regulatory & Pricing: Ongoing risks related to the Inflation Reduction Act (IRA), potential tariffs on imported pharmaceuticals, and pricing pressures from government payers.
- Legal: Significant pending litigation includes antitrust/consumer protection class actions and product liability suits related to HIV and hepatitis products. A qui tam lawsuit regarding HCV sales was dismissed in September 2025 but is under appeal.
- Development: FDA placed a clinical hold on HIV treatment trials for GS-1720 and GS-4182 in June 2025.
Investor Verification Checklist
- IPR&D Impairments: Verify the magnitude of impairment charges in Q3 2024 ($1.8 billion) versus Q3 2025 ($0) to understand the volatility in net income.
- Revenue Recognition: Confirm the details of the $400 million previously constrained revenue recognized in Q3 2025 and its sustainability.
- Trodelvy Outlook: Assess the impact of the ASCENT-07 primary endpoint failure on future revenue projections and potential future impairment risks for the Trodelvy asset.
- Patent Exclusivity: Review the terms of the Biktarvy generic settlement to confirm the April 2036 entry date and any acceleration clauses.
- Cash Flow vs. Net Income: Note that operating cash flow decreased 15% year-over-year for the nine-month period despite higher net income, driven by inventory build-up and timing of collections.